Lead Product(s) : EBX-102-02
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EnteroBiotix Reports Positive Phase 2a Results for EBX-102-02 in IBS
Details : EBX-102-02, the company’s next-generation full-spectrum microbiome product, currently under clinical trials in adults with irritable bowel syndrome with constipation (IBS-C).
Product Name : EBX-102-02
Product Type : Probiotic
Upfront Cash : Inapplicable
March 18, 2025
Lead Product(s) : EBX-102-02
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EBX-102-02
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome
Details : EBX-102-02 is a next-generation, full-spectrum drug candidate that restore and fortify the microbiome. It is being evaluated for irritable bowel syndrome.
Product Name : EBX-102-02
Product Type : Probiotic
Upfront Cash : Inapplicable
November 18, 2024
Lead Product(s) : EBX-102-02
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EBX-102-02
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Thairm Bio
Deal Size : $34.0 million
Deal Type : Financing
EnteroBiotix Completes £27m Financing Round to Advance Clinical Trials
Details : The net proceeds will advance EBX’s lead candidate, EBX-102-02, a next-generation drug with diverse microbial ecosystems, through a Phase 2 trial in Irritable Bowel Syndrome.
Product Name : EBX-102-02
Product Type : Probiotic
Upfront Cash : Undisclosed
April 04, 2024
Lead Product(s) : EBX-102-02
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Thairm Bio
Deal Size : $34.0 million
Deal Type : Financing
Lead Product(s) : EBX-102-02
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EnteroBiotix Initiates Phase 2 Study of EBX-102-02 for Irritable Bowel Syndrome
Details : EBX-102-02 is a next-gen drug candidate with diverse microbial ecosystems, evaluated for restoring the microbiome in patients with irritable bowel syndrome.
Product Name : EBX-102-02
Product Type : Probiotic
Upfront Cash : Inapplicable
March 04, 2024
Lead Product(s) : EBX-102-02
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Blautia Hydrogenotrophica
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results demonstrate changes in gut microbiome structure following administration of Blautix (Blautia Hydrogenotrophica) in both IBS-C and IBS-D patients.
Product Name : Blautix
Product Type : Microorganism
Upfront Cash : Inapplicable
September 12, 2021
Lead Product(s) : Blautia Hydrogenotrophica
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Blautia Hydrogenotrophica
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
4D pharma to Present Additional Data from Phase II Study of Blautix for Irritable Bowel Syndrome
Details : In Phase II trial, where Blautix demonstrated signals of clinical activity in both IBS-C and IBS-D, and a highly favorable safety and tolerability profile.
Product Name : Blautix
Product Type : Microorganism
Upfront Cash : Inapplicable
May 17, 2021
Lead Product(s) : Blautia Hydrogenotrophica
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Blautia Hydrogenotrophica
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The phase II trial showed that Blautix treatment resulted in: A statistically significant increase in overall response in pre-planned analysis of the combined IBS-C/D group compared to placebo; A positive, increase in overall response in both IBS-C and I...
Product Name : Blautix
Product Type : Microorganism
Upfront Cash : Inapplicable
July 10, 2020
Lead Product(s) : Blautia Hydrogenotrophica
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable